NSO-07: Management Considerations for Dermatologic Toxicities Associated With Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
NSO-04: Characterising sleep disturbances with actigraphy in those receiving steroids for the treatment of multiple myeloma: Findings from a pilot study